Pubfacts - Scientific Publication Data
  • Categories
  • |
  • Journals
  • |
  • Authors
  • Login
  • Categories
  • Journals

Search Our Scientific Publications & Authors

Publications
  • Publications
  • Authors
find publications by category +
Translate page:

Predicting sinusoidal obstruction syndrome after allogeneic stem cell transplantation with the EASIX biomarker panel.

Authors:
Sihe Jiang Olaf Penack Tobias Terzer David Schult Joshua Majer-Lauterbach Aleksandar Radujkovic Igor W Blau Lars Bullinger Carsten Müller-Tidow Peter Dreger Thomas Luft

Haematologica 2021 Feb 1;106(2):446-453. Epub 2021 Feb 1.

Medicine V, University Hospital Heidelberg, Heidelberg, Germany.

No biomarker panel is established for prediction of sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD), a major complication of allogeneic stem cell transplantation (alloSCT). We compared the potential of the Endothelial Activation and Stress Index (EASIX), based on lactate dehydrogenase, creatinine, and thrombocytes, with that of the SOS/VOD CIBMTR clinical risk score to predict SOS/VOD in two independent cohorts. In a third cohort, we studied the impact of endothelium-active prophylaxis with pravastatin and ursodeoxycholic acid (UDA) on SOS/VOD risk. The cumulative incidence of SOS/VOD within 28 days after alloSCT in the training cohort (Berlin, 2013-2015, n=446) and in the validation cohort (Heidelberg, 2002-2009, n=380) was 9.6% and 8.4%, respectively. In both cohorts, EASIX assessed at the day of alloSCT (EASIX-d0) was significantly associated with SOS/VOD incidence (p<0.0001), overall survival (OS) and non-relapse mortality (NRM). In contrast, the CIBMTR score showed no statistically significant association with SOS/VOD incidence, and did not predict OS and NRM. In patients receiving pravastatin/UDA, the cumulative incidence of SOS/VOD was significantly lower at 1.7% (p<0.0001, Heidelberg, 2010-2015, n=359) than in the two cohorts not receiving pravastatin/UDA. The protective effect was most pronounced in patients with high EASIX-d0. The cumulative SOS/VOD incidence in the highest EASIX-d0 quartiles were 18.1% and 16.8% in both cohorts without endothelial prophylaxis as compared to 2.2% in patients with pravastatin/UDA prophylaxis (p<0.0001). EASIX-d0 is the first validated biomarker for defining a subpopulation of alloSCT recipients at high risk for SOS/VOD. Statin/UDA endothelial prophylaxis could constitute a prophylactic measure for patients at increased SOS/VOD risk.

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2019.238790DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7849560PMC
February 2021

Publication Analysis

Top Keywords

stem cell
8
allogeneic stem
8
sinusoidal obstruction
8
biomarker panel
8
cell transplantation
8
sos/vod
6
sos/vod cibmtr
4
risk cumulative
4
thrombocytes sos/vod
4
heidelberg 2002-2009
4
risk score
4
training cohort
4
clinical risk
4
cibmtr clinical
4
creatinine thrombocytes
4
dehydrogenase creatinine
4
easix based
4
96% 84%
4
stress easix
4
activation stress
4

Keyword Occurance

Similar Publications

© 2021 PubFacts.
  • About PubFacts
  • Privacy Policy
  • Sitemap